Extreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytes.

Lever, Michael; McEntyre, Christopher J; George, Peter M; Slow, Sandy; Elmslie, Jane L; Lunt, Helen; Chambers, Stephen T; Parry-Strong, Amber; Krebs, Jeremy D

Lever, Michael; McEntyre, Christopher J; George, Peter M; Slow, Sandy; Elmslie, Jane L; Lunt, Helen; Chambers, Stephen T; Parry-Strong, Amber; Krebs, Jeremy D.

Afiliación

Lever M; Biochemistry Unit, Canterbury Health Laboratories, P.O. Box 151, Christchurch, 8140, New Zealand, michael.lever@otago.ac.nz.

Cardiovasc Drugs Ther ; 28(5): 459-68, 2014 Oct.

Article en En | MEDLINE | ID: mdl-25060556

Asunto(s)

Betaína/orina; Bezafibrato/efectos adversos; Colina/orina; Diabetes Mellitus Tipo 2/orina; Hipolipemiantes/efectos adversos; Sarcosina/análogos & derivados; Adulto; Anciano; Betaína/sangre; Diabetes Mellitus Tipo 2/sangre; Femenino; Glicerilfosforilcolina/orina; Homocisteína/sangre; Humanos; Inositol/orina; Masculino; Persona de Mediana Edad; Sarcosina/orina; Taurina/orina; Adulto Joven

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sarcosina / Betaína / Bezafibrato / Colina / Diabetes Mellitus Tipo 2 / Hipolipemiantes Tipo de estudio: Risk_factors_studies Idioma: En Revista: Cardiovasc Drugs Ther Año: 2014 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google